Category: Biopharmaceutical

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

Biologics, often referred to as biopharmaceuticals or large molecules, are manufactured in the biological system, such as microorganisms, plants, or animal cells. Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~12%, the industry stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing demand for novel

China, epicenter of the COVID-19, is the world’s second largest pharmaceutical market and accounts for 20 % of the global output of APIs. With over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials, investigating a variety of biologics and biosimilars, being underway in this region, China’s biopharma market is

Well before the COVID-19 pandemic, there were warning signs of an imminent US recession. The ongoing pandemic, and trade conflicts between the US. and China, and the US and Europe have just accelerated the fall of the global economy. In fact, as per the United Nations, the world economy is expected to go into recession

I was recently involved in a discussion with the global outsourcing manager of one of the big pharma companies. The premise of the discussion was around the criteria that big Biopharma Contract players follow for choosing a supplier for their products. One key question that came up in the discussion was whether one-stop-shops are really

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the CMOs in this domain. It is worth highlighting that, since 2000, more than 115 new

The development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. This has led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers. The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 – 2027’ report provides an extensive study of the contract manufacturing